Pfizer has agreed to acquire Global Blood Therapeutics (GBT) for $5.4 billion cash, in a deal that continues the pharma giant’s spate of acquisitions made possible by the billions of dollars ...

A month has gone by since the last earnings report for Global Blood Therapeutics (GBT). Shares have added about 15.4% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Under the terms of the transaction, Pfizer will acquire all the outstanding shares of GBT for $68.50 per share in cash, for a total enterprise value of approximately $5.4 billion, including debt ...

Pfizer is on the brink of announcing a deal to buy Global Blood Therapeutics (GBT) and its oral therapy Oxbryta for sickle cell disease for around $5 billion, according to press reports.

Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.

Before settling on a $5.4 billion price tag for Global Blood Therapeutics, ... GBT’s SCD franchise could reach $2.7 billion in annual sales by 2030, according to SVB’s estimates, ...

Global Blood Therapeutics, Inc. (GBT) Q4 2020 Results Earnings Conference Call February 24, 2021 4:30 PM ETCompany ParticipantsSteven Immergut - Senior Vice ...